tsh biopharmoration Ltd (TWO:8432) — Market Cap & Net Worth
Market Cap & Net Worth: tsh biopharmoration Ltd (8432)
tsh biopharmoration Ltd (TWO:8432) has a market capitalization of $60.61 Million (NT$1.92 Billion) as of September 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #21254 globally and #1280 in its home market, demonstrating a -0.40% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying tsh biopharmoration Ltd's stock price NT$50.10 by its total outstanding shares 38398000 (38.40 Million). Also see tsh biopharmoration Ltd asset portfolio for a full breakdown of the balance sheet.
tsh biopharmoration Ltd Market Cap History: 2015 to 2026
tsh biopharmoration Ltd's market capitalization history from 2015 to 2026. Data shows growth from $69.99 Million to $60.61 Million (2.76% CAGR). Also see 8432 cash flow conversion for how efficiently the company converts equity into cash flow.
tsh biopharmoration Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how tsh biopharmoration Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 8432 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.07x
tsh biopharmoration Ltd's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.66x
tsh biopharmoration Ltd's market cap is 0.66 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $58.85 Million | $486.28 Million | $64.97 Million | 0.12x | 0.91x |
| 2018 | $74.44 Million | $515.65 Million | $57.78 Million | 0.14x | 1.29x |
| 2019 | $82.28 Million | $507.67 Million | $85.33 Million | 0.16x | 0.96x |
| 2020 | $63.42 Million | $447.86 Million | $61.57 Million | 0.14x | 1.03x |
| 2021 | $50.14 Million | $413.48 Million | $47.11 Million | 0.12x | 1.06x |
| 2022 | $55.52 Million | $741.07 Million | $61.89 Million | 0.07x | 0.90x |
| 2023 | $60.85 Million | $810.92 Million | $61.99 Million | 0.08x | 0.98x |
| 2024 | $74.16 Million | $1.12 Billion | $113.09 Million | 0.07x | 0.66x |
Competitor Companies of 8432 by Market Capitalization
Companies near tsh biopharmoration Ltd in the global market cap rankings as of September 18, 2026. Review tsh biopharmoration Ltd tangible equity quality to assess the quality of the company's equity after excluding intangible assets.
Key companies related to tsh biopharmoration Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #519 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #633 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #640 globally with a market cap of $43.16 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.62 Billion USD ( CN¥277.61 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #519 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #633 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #640 | GALDERMA GROUP AG | NYSE:GALDY | $43.16 Billion | $37.02 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.62 Billion | CN¥43.52 |
tsh biopharmoration Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, tsh biopharmoration Ltd's market cap moved from $69.99 Million to $ 60.61 Million, with a yearly change of 2.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$60.61 Million | -14.36% |
| 2025 | NT$70.77 Million | -4.57% |
| 2024 | NT$74.16 Million | +21.87% |
| 2023 | NT$60.85 Million | +9.60% |
| 2022 | NT$55.52 Million | +10.73% |
| 2021 | NT$50.14 Million | -20.93% |
| 2020 | NT$63.42 Million | -22.92% |
| 2019 | NT$82.28 Million | +10.52% |
| 2018 | NT$74.44 Million | +26.50% |
| 2017 | NT$58.85 Million | -14.87% |
| 2016 | NT$69.14 Million | -1.22% |
| 2015 | NT$69.99 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of tsh biopharmoration Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $60.61 Million USD |
| MoneyControl | $60.61 Million USD |
| MarketWatch | $60.61 Million USD |
| marketcap.company | $60.61 Million USD |
| Reuters | $60.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About tsh biopharmoration Ltd
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid … Read more